Patent Trends across Circulating Tumor Cells - Genetic Technology TOE

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts life sciences patent trends across circulating tumor cell based technologies. A strategic overview of the innovative patents and disruptive technologies is provided, with key company profiles of some important companies in the space of circulating tumor cells.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alt

Table of Contents

Patent Trends across Circulating Tumor Cells - Genetic Technology TOEOverview – Circulating Tumor Cells Circulating Tumor Cells and their Metastasis PotentialPatent Trend-Based ProfilesNorth America has the Highest Patent Activity across Circulating Tumor Cell Technologies Key Patents from among CTC Technologies (2013-2016)Key Patents from among CTC Technologies (2013-2016) Epic Sciences’ Patented Technology allows Easy Detection of CTCs across all CancersJanssen Diagnostics Provides FDA Approved Test for Assessment of cancer prognosisAppendixIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.